ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home ctDNA

Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

Kara Nyberg, PhD
on: October 09, 2020In: Meeting News
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more


ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Kara Nyberg, PhD
on: October 09, 2020In: Meeting News
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more

FDA Perspectives on the Use of Liquid Biopsy in NSCLC

Kara Nyberg, PhD
on: October 09, 2020In: Industry News & Regulatory Approvals, Meeting News
FDA Perspectives on the Use of Liquid Biopsy in NSCLC

The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

on: June 24, 2020In: Meeting News
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based […] Read more

Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits

on: April 15, 2020In: Evolving Standards of Care
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits

Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. […] Read more

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC

on: December 10, 2019In: Evolving Standards of Care
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC

By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy […] Read more

Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy

on: December 10, 2019In: Evolving Standards of Care
Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy

Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy